Ingredion delivered record full-year operating income of $1.028 billion and a 4.5% increase in adjusted EPS, despite a 3% decline in net sales to $7.2 billion, driven by a 16% increase in operating income from the Texture and Healthful Solutions segment and record margins in LatAm. However, the company faced significant headwinds in its Food and Industrial Ingredients U.S./Canada segment, where operational challenges at the Argo facility reduced operating income by $40 million for the year and contributed to a 7% volume decline in Q4. For 2026, management guided for adjusted EPS between $11.00 and $11.80, anticipating a gradual recovery at Argo and continued volume growth in specialty ingredients, though they noted that manufacturing inflation is not yet fully covered by pricing.
| Metric | Value | Change |
|---|---|---|
| Q4 Net Sales | $1.8 billion | -2% |
| FY Net Sales | $7.2 billion | -3% |
| FY Adjusted Operating Income | $1.028 billion | Record High |
| FY Adjusted EPS Growth | 4.5% | Increase |
| FY Gross Margin | 25.3% | Expanded |
| FY Cash from Operations | $944 million | Strong |
| T&H Volume Growth | 4% | Q4 / FY |
| Argo Facility Impact (FY) | $40 million | Headwind |
| Share Repurchases (FY) | $224 million | Exceeded Target |
Ingredion's Texture and Healthful Solutions (T&H) segment remains the primary growth engine, posting its seventh straight quarter of volume growth (+4%) and a 16% increase in operating income. Management emphasized that 'clean label remains one of the food industry's fastest-growing areas,' and their solutions selling approach is driving higher-margin sales. The segment's operating margin expanded by over 200 basis points to 16.9%, validating the strategy to pivot away from commodity volumes toward value-added ingredients.
The company is aggressively pursuing operational excellence, delivering $59 million in Cost2Compete run rate savings in 2025, exceeding its $50 million target. Management is transitioning this focus toward 'long-term enterprise productivity' to drive efficiency. Additionally, strategic capital investments, such as the starch modernization project in Indianapolis and the expansion of the Belcamp blending center, are expected to reduce costs and drive new capacity, supporting future margin expansion.
Protein fortification has emerged as a significant growth driver, with the business delivering a record year where net sales growth exceeded 40% and operating loss improved by more than $20 million. Management stated, 'We see this business representing a viable long-term growth opportunity for us, supported by strong and clear consumer pull.' This segment is benefiting from the 'positive impact' of GLP-1 weight loss drugs, positioning Ingredion to capitalize on shifting consumer dietary trends.
Management is executing a complex turnaround at the Argo facility, the largest plant in the U.S./Canada segment. While the issues caused a $40 million headwind in 2025, management detailed a 'systematic' recovery plan. They noted that while January was a 'rough start,' the plant is currently running well, and they expect to recover approximately $20 million of the lost earnings in the back half of 2026, signaling a potential inflection point for earnings in the second half of the year.
The Argo facility continues to be a significant operational liability, causing a $40 million operating income hit in 2025 ($16 million in Q4 alone). Management warned that the plant will face 'continued challenges through the first quarter' with an estimated additional $10 million to $15 million impact in Q1 2026. The admission that 'January was not as strong as we had anticipated' raises concerns about the stability of the recovery timeline and the reliability of the facility.
Management admitted a lack of full pricing power relative to inflation, stating, 'We anticipate that we will not fully cover the expected manufacturing cost inflation.' Specifically, they cited higher natural gas and labor rates that are 'playing against our COGS rate of change.' This inability to pass through costs could pressure margins in 2026, particularly if the volume recovery in North America is slower than expected.
The Food and Industrial Ingredients U.S./Canada segment is experiencing broad demand softness beyond just Argo. Management noted 'industry volume demand for sweeteners was down throughout the second half' and that customers are signaling lower unit volumes due to 'pricing actions and the fact that U.S. consumers continue to struggle with affordability.' This macro pressure, combined with a 'measured' outlook for the segment, suggests a sluggish recovery for the core North American business.
The announced retirement of CFO Jim Gray introduces a degree of uncertainty during a critical period of operational turnaround. While the transition is planned, the loss of a nine-year veteran who has been an 'invaluable partner' comes as the company navigates complex operational fixes at Argo and shifting macroeconomic conditions, potentially distracting management during a sensitive time.
Overall: Management displayed a tone of resilience and disciplined execution, acknowledging the severity of the Argo facility issues while maintaining confidence in the long-term strategic pivot towards higher-value specialty ingredients. There was a clear shift from the prepared remarks, which highlighted record results, to a more cautious and pragmatic tone during the Q&A regarding the timing of the Argo recovery and the ability to pass through inflation.
Confidence: MEDIUM - Management is confident in the Texture & Healthful strategy and LatAm resilience but expressed caution regarding the operational fix at Argo and the near-term macro environment, using language like 'gradual recovery' and 'rough start' for January.
$11.00 to $11.80
Up low single digits to mid-single digits
Up low single digits
$820 million to $940 million
$400 million to $440 million
Down mid-double digits
Hedging & Uncertainty: Management utilized frequent hedging language regarding the Argo recovery and 2026 outlook, using qualifiers such as 'stubbornly persisted,' 'gradual recovery,' and 'rough start' to manage expectations. When discussing 2026 guidance, they relied on probabilistic language like 'anticipate,' 'estimate,' and 'should,' rather than definitive commitments. For example, Jim Zallie stated, 'We expect a gradual recovery,' and regarding inflation, he noted, 'We anticipate that we will not fully cover the expected manufacturing cost inflation.' This pattern suggests management is confident in the long-term strategy but is wary of promising a quick fix to the operational issues, opting for a cautious, under-promise approach to guidance.
Clean label remains one of the food industry's fastest-growing areas... - James Zallie, President and CEO
Argo facility... operational difficulties... stubbornly persisted throughout the fourth quarter. - James Zallie, President and CEO
We anticipate that we will not fully cover the expected manufacturing cost inflation. - James Zallie, President and CEO
January was not as strong as we had anticipated. - James Zallie, President and CEO
We were not fully able to cover anticipated manufacturing cost inflation. - James Zallie, President and CEO
We anticipate Food and Industrial Ingredients in U.S./Canada to meaningfully overcome its operational setbacks as we remain laser-focused on stabilizing Argo. - James Zallie, President and CEO
Our 2026 financing cost estimate is in the range of $40 million to $50 million... - Jim Gray, Executive Vice President and CFO
We delivered $59 million of Cost2Compete run rate savings, exceeding our previously stated $50 million savings target. - James Zallie, President and CEO
Analyst Sentiment: Analysts were highly focused on the mechanics of the Argo facility turnaround, pressing for specific quantification of the headwinds versus volume declines. There was also significant interest in the sustainability of the Texture & Healthful margins and the specific impact of the new sugar tax in Mexico.
Management Responses: Management was transparent and data-rich in their responses, providing specific dollar amounts for the Argo impact ($16M in Q4, $40M FY) and breaking down volume declines (2/3 Argo, 1/3 sweeteners). They effectively used the Q&A to reiterate the strength of the specialty portfolio while managing expectations on the timing of the North American recovery.
Argo Facility Impact: Analysts sought to understand the split between operational issues and market softness. Management clarified that Q4 volume decline was '2/3 Argo, 1/3 sweetener volumes' and detailed the $40 million full-year impact.
Pricing and Inflation: Analysts questioned the ability to maintain margins given raw material deflation and manufacturing inflation. Management admitted they were 'not fully able to cover anticipated manufacturing cost inflation' in 2026 contracts.
LatAm Dynamics: Questions focused on the impact of the Mexican peso strength and new sugar taxes. Management noted they are 'dollar functional' in Mexico, which creates a headwind from a strong peso, but they expect World Cup volumes to offset some softness.
Long-term Algorithm: Analysts asked when the company would return to its long-term growth algorithm. Management indicated a reset to 2025 results is likely, with a return to 17-18% margins in U.S./Canada expected by 2027/2028.
Ingredion is successfully executing its strategic pivot toward higher-value Texture and Healthful Solutions, which now drives the majority of its profitability and provides a strong hedge against commodity cyclicality. The company delivered record operating income and margins in 2025, demonstrating the resilience of its business model. However, the investment thesis is currently capped by significant operational execution risk at the Argo facility, which will depress earnings in the first half of 2026, and a lack of near-term pricing power to offset manufacturing inflation. While the long-term story remains intact, the guidance for flat operating income growth in 2026 suggests a 'show-me' period where investors must wait for tangible proof of the Argo stabilization before multiple expansion can occur.
Management noted that 'U.S. consumers continue to struggle with affordability,' which is leading customers to signal lower unit volumes. This pressure is contributing to softness in beverage sweetener demand.
The company faced a 'volatile trade and tariff environment' in 2025, which caused customers to adjust pricing and volumes in categories like soda and beer. However, Ingredion was 'minimally directly impacted' because 80% of production is locally made and sold.
The rise of GLP-1 weight loss drugs is having a 'positive impact' on Ingredion's protein fortification business, which saw sales grow 40% in 2025. Management views this as a 'viable long-term growth opportunity' supported by consumer pull.
A strong Mexican peso is creating a transactional headwind for the LatAm segment. Because the company is dollar functional in Mexico, a stronger peso inflates local manufacturing and operating expenses.